Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesBeginning Cash BalanceCash from Financing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

InMed Pharmaceuticals (INM) Change in Receivables: 2020-2025

Historic Change in Receivables for InMed Pharmaceuticals (INM) over the last 6 years, with Jun 2025 value amounting to $114,690.

  • InMed Pharmaceuticals' Change in Receivables fell 80.65% to -$122,160 in Q3 2025 from the same period last year, while for Sep 2025 it was $60,154, marking a year-over-year decrease of 49.60%. This contributed to the annual value of $114,690 for FY2025, which is 24.07% up from last year.
  • InMed Pharmaceuticals' Change in Receivables amounted to $114,690 in FY2025, which was up 24.07% from $92,439 recorded in FY2024.
  • InMed Pharmaceuticals' Change in Receivables' 5-year high stood at $219,147 during FY2023, with a 5-year trough of -$40,198 in FY2021.
  • For the 3-year period, InMed Pharmaceuticals' Change in Receivables averaged around $142,092, with its median value being $114,690 (2025).
  • Its Change in Receivables has fluctuated over the past 5 years, first tumbled by 132.72% in 2021, then soared by 447.76% in 2023.
  • Over the past 5 years, InMed Pharmaceuticals' Change in Receivables (Yearly) stood at -$40,198 in 2021, then skyrocketed by 199.53% to $40,008 in 2022, then surged by 447.76% to $219,147 in 2023, then plummeted by 57.82% to $92,439 in 2024, then increased by 24.07% to $114,690 in 2025.